Leukemia Chronic Lymphocytic Susceptibility To 5 C2675514
Inherited genetic factor potentially associated with higher risk of chronic lymphocytic leukemia, a slow-growing blood cell cancer.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(hematologic)Generalized symptoms
(hematologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Lymphadenopathy
(hematologic)Recurrent infections
(hematologic)Night sweats
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Watchful Waiting with Regular Monitoring
For mild CLL, active surveillance with periodic blood tests and clinical evaluations is often the initial approach, monitoring for disease progression without immediate intervention.
Healthy Lifestyle Modifications
Adopting a balanced lifestyle including regular exercise, stress management, and adequate sleep to support immune function and overall wellbeing.
Additional treatment options
Anti-inflammatory Diet
Consuming a nutrient-rich diet with emphasis on fruits, vegetables, whole grains, and omega-3 fatty acids to support immune health and reduce inflammation.
dietaryStress Reduction Techniques
Mind-body practices such as meditation, yoga, or breathing exercises to reduce stress and potentially improve immune function.
complementaryImmunomodulatory Therapy
For cases showing progression, targeted therapies may be prescribed to modulate immune response and control disease activity.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Leukemia Chronic Lymphocytic Susceptibility To 5 C2675514?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Halpern J, Arav-Boger R, Rund D. Inherited susceptibility to chronic lymphocytic leukemia: evidence-based clinical practice guidelines. Blood Adv. 2022.
Goldin LR, Camp NJ, Slager SL. Genetic epidemiology of familial chronic lymphocytic leukemia. Leukemia. 2020.
Berndt SI, Skibola CF, Joseph V. Genome-wide association study identifies novel susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2021.
Mayer SP, Gribben JG. Germline mutations and chronic lymphocytic leukemia: clinical implications. J Clin Oncol. 2023.
Medication Comparisons
Compare medications used to treat Leukemia Chronic Lymphocytic Susceptibility To 5 C2675514. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy